A Single-arm, Open, Single-center, Prospective and Exploratory Clinical Study of Surufatinib Combined With Tislelizumab in the Treatment of Advanced Lung Cancer With Neuroendocrine Differentiation
Latest Information Update: 20 May 2024
At a glance
- Drugs Surufatinib (Primary) ; Tislelizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 20 May 2024 New trial record